Sean McClain, founder & CEO of AbSci, founded the company in 2011 with a bold vision to unify biologic drug discovery and development processes, taking a synthetic biology approach and working with the industry’s original biomanufacturing organism, E. coli. Sean developed AbSci’s Protein Printing technology™ which combines the versatility of E. coli SoluPro® with a powerful synthetic biology platform for generation of high-diversity strain libraries and cutting-edge high-throughput screening assays. Today, informed by AbSci’s deep learning Denovium Engine™, AbSci’s Protein Printing platform enables discovery of novel biologics in the desired protein scaffold format, and in the scalable production cell line, in a matter of weeks. Under Sean’s leadership AbSci has grown to more than 100 employees, raised more than $230M, acquired deep learning pioneer Denovium, and established partnerships with industry-leading pharmaceutical and biotech companies. Sean is an alumnus of the University of Arizona where he studied Biochemistry and Molecular Biology. He has been recognized as part of the 2019 Forbes 30 Under 30 cohort in Science and named as an Entrepreneur Of The Year 2020 Pacific Northwest Region Award Winner. Sean serves as a board member for the Oregon Bioscience Association, the Oregon Translational Research and Development Institute, and Life Science Washington.